{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:34:00Z","timestamp":1794576840729,"version":"4.9.1"},"reference-count":101,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017577","name":"CTI BioPharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/17474086.2022.2112565","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T03:06:40Z","timestamp":1660878400000},"page":"671-684","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":60,"title":["Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23690"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24098"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2208-2"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13005"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106338"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.01.008"},{"key":"cit0015","unstructured":"TriNetX. Dataworks US EMR database [cited Apr 2022]. Available from: https:\/\/trinetx.com\/"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8833"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14601"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.10.002"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"cit0020","unstructured":"Gerds AT, Gotlib J, Bose P. et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology Myeloproliferative Neoplasms. Version 3.2022. [cited 2 Jun 2022]. Available from: Accessed 02 Jun 2022 https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines. Version 3.2022."},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.323"},{"key":"cit0022","volume-title":"Incyte corporation","year":"2021"},{"key":"cit0023","unstructured":"Celgene Corporation INREBIC\u00ae (fedratinib) US Prescribing Information; 2021. Celgene."},{"key":"cit0024","unstructured":"CTI BioPharma Announces FDA Accelerated Approval of VONJO\u2122 (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia [Internet]. Feb 28, 2022 [cited June 7, 2022]. [Internet]. Feb 28, 2022: https:\/\/investors.ctibiopharma.com\/news-releases\/news-release-details\/cti-biopharma-announces-fda-accelerated-approval-vonjotm"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.12.003"},{"key":"cit0026","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet]. Sep 1, 2021 cited Jul 20, 2022]. [Internet]. Sep 1, 2021: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"cit0027","volume-title":"VONJOTM (pacritinib) US prescribing information","author":"CTI BioPharma Corp","year":"2022"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S110702"},{"key":"cit0029","unstructured":"CTI BioPharma Corp. Data on file - preclinical data report. 2022."},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01815-2"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"cit0032","unstructured":"FDA Approves Incyte\u2019s Jakafi\n                      TM\n                      (ruxolitinib) for Patients with Nyelofibrosis. [cited 2011 Nov 11]. Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/fda-approves-incytes-jakafitm-ruxolitinib-patients-myelofibrosis"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0954-2"},{"key":"cit0036","unstructured":"U.S. FDA Approves INREBIC\u00ae (Fedratinib) as first new treatment in nearly a decade for patients with myelofibrosis [Internet] Aug 16, 2019. [cited 2022 Jun 7]. https:\/\/ir.celgene.com\/press-releases-archive\/press-release-details\/2019\/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis\/default.aspx"},{"key":"cit0037","unstructured":"A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM). 2019 [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04173494"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004611"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16462"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204602"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.016"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147614"},{"key":"cit0050","doi-asserted-by":"crossref","unstructured":"Gupta V, Yacoub A, Verstovsek S, et al. Safety and tolerability results from the phase 3b FREEDOM trial of fedratinib (FEDR), an oral, selective JAK2 inhibitor, in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). Presented at EHA 2022.","DOI":"10.1097\/01.HS9.0000847036.30498.e9"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7002"},{"key":"cit0055","unstructured":"Sierra OncologyAnnounces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis Jan 25, 2022 [cited 2022 Jun 7]. Jan 25, 2022: https:\/\/investor.sierraoncology.com\/news-releases\/news-details\/2022\/Sierra-Oncology-Announces-Momelotinib-Achieved-Statistically-Significant-Benefit-on-Symptoms-Anemia-and-Splenic-Size-in-the-Pivotal-MOMENTUM-Study-for-Myelofibrosis\/default.aspx"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7061"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3519"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.821344"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405097"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-216044"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001271"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0318-096R"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0379-y"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018026450"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.11.004"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77347"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-730556"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26058"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.148"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000954"},{"key":"cit0073","unstructured":"Fedratinib NDA 2019 [cited 2022 Jun 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212327Orig1s000MultidisciplineR.pdf"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115407"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0112-2"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24978"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(16)33004-0"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.43"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.01.050"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.570.570"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410369200"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-CT159"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"key":"cit0086","author":"Venugopal S","journal-title":"Blood Adv"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0367-x"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4080.4080"},{"key":"cit0089","unstructured":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis PPVM, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) (NCT03165734). 2017 [cited Jun 7, 2022]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03165734"},{"key":"cit0090","unstructured":"CTI BioPharma Corp. Data on File - Clinical Study Report: PAC325 (PERSIST\u20131). 2016."},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144505"},{"key":"cit0092","unstructured":"CTI BioPharma Corp. Data on file - clinical study report: PAC326 (PERSIST\u20132). 2016."},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.015"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146675"},{"issue":"23","key":"cit0095","first-page":"5929","volume":"4","author":"Tremblay D","journal-title":"Blood Adv"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.45"},{"key":"cit0097","author":"Verstovsek S","journal-title":"Haematologica"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7058"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151395"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01405-z"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01446-4"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2022.2112565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T06:06:47Z","timestamp":1662962807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2022.2112565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":101,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/17474086.2022.2112565"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2022.2112565","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}